- Home
- SNDX vs CNNE Comparison
SNDX vs CNNE Comparison
Compare SNDX & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- CNNE
- Stock Information
- Founded
- SNDX 2005
- CNNE 2014
- Country
- SNDX United States
- CNNE United States
- Employees
- SNDX N/A
- CNNE N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- CNNE Restaurants
- Sector
- SNDX Health Care
- CNNE Consumer Discretionary
- Exchange
- SNDX Nasdaq
- CNNE Nasdaq
- Market Cap
- SNDX 1.3B
- CNNE 1.1B
- IPO Year
- SNDX 2016
- CNNE N/A
- Fundamental
- Price
- SNDX $16.42
- CNNE $18.63
- Analyst Decision
- SNDX Strong Buy
- CNNE Buy
- Analyst Count
- SNDX 10
- CNNE 3
- Target Price
- SNDX $38.40
- CNNE $23.33
- AVG Volume (30 Days)
- SNDX 1.9M
- CNNE 733.4K
- Earning Date
- SNDX 11-04-2025
- CNNE 11-11-2025
- Dividend Yield
- SNDX N/A
- CNNE 3.23%
- EPS Growth
- SNDX N/A
- CNNE N/A
- EPS
- SNDX N/A
- CNNE N/A
- Revenue
- SNDX $77,933,000.00
- CNNE $437,200,000.00
- Revenue This Year
- SNDX $642.36
- CNNE N/A
- Revenue Next Year
- SNDX $108.58
- CNNE N/A
- P/E Ratio
- SNDX N/A
- CNNE N/A
- Revenue Growth
- SNDX 2126.66
- CNNE N/A
- 52 Week Low
- SNDX $8.58
- CNNE $15.92
- 52 Week High
- SNDX $22.50
- CNNE $22.36
- Technical
- Relative Strength Index (RSI)
- SNDX 61.98
- CNNE 47.15
- Support Level
- SNDX $14.93
- CNNE $17.95
- Resistance Level
- SNDX $15.99
- CNNE $18.70
- Average True Range (ATR)
- SNDX 0.70
- CNNE 0.44
- MACD
- SNDX 0.04
- CNNE 0.02
- Stochastic Oscillator
- SNDX 83.26
- CNNE 33.07
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.